Session: 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster III
Hematology Disease Topics & Pathways:
Genomics, Diseases, Biological Processes, Myeloid Malignancies
This study enrolled 603 patients diagnosed with treatable AML, excluding acute promyelocytic leukemia, between Feb. 2017 and Jun. 2021 from 17 institutions. Among these, paired CR samples were available for 343 patients who were eligible for NGS at diagnosis and after chemotherapies. We detected germline variants in 19 patients (5.5%). The most frequent germline mutations were in DDX41 (n=11, 58%) followed by DNAH5 (n=3, 16%), CEBPA and TP53 (both n=2, 11%), and MPL and GATA2 (both n=1, 5%). One patient harbored both TP53 and DNAH5 germline mutations. The mean VAF at diagnosis and CR samples were 48.9% [inter-quantile range (IQR): 47.8%-49.9%] and 48.0% (IQR: 47.6%-49.7%) respectively. Compared with non-germline mutated patients, patients with germline mutations were more hypoplastic (50% vs 80%, P < 0.001), and low bone marrow blast counts (34% vs. 65%, P=0.004). Germline mutations were not observed in the favorable cytogenetic risk group (0% vs. 23.1%, P= 0.03), and were rarely detected in 2022 European LeukemiaNet favorable risk group (5.3% vs. 47.5%, P <0.001), compared with non-germline mutated patients. Intensive chemotherapy was more frequently administered in the non-germline mutated group (P=0.022) but, there was no difference in the rate of allogeneic transplants between the two groups (P>0.05). Comparing survival rates, there was no difference between two groups that received intensive chemotherapy, nor was there a difference for those who underwent allogeneic transplantation (all, P>0.05).
In conclusion, NGS analysis using matched CR samples proves to be an invaluable tool in detecting germline mutations. Since patients with germline mutations are rarely classified into the favorable risk category, most patients in this group should consider allogeneic transplantation. Although patients with germline mutations did not show significant prognostic differences in treatment outcomes due to the small number of patients, more studies involving a larger cohort are needed to determine the role of allogeneic transplantation.
Disclosures: Lee: NGnebio: Current Employment. Kim: BMS & Celgene, Novartis, APLC, AbbVie, Astellas, Janssen, Handok, Pfizer, Sanofi Genzyme, AML-Hub, Daiichi Sankyo and APBMT: Membership on an entity's Board of Directors or advisory committees; AbbVie, Astellas, BMS, Handok, Novartis, AML-Hub, Jazz Pharmaceuticals and Takeda: Honoraria, Speakers Bureau; AbbVie, AIMS Bioscience, AML-Hub, Astellas, BMS & Celgene, Boryung Pharm Co., Daiichi Sankyo, Janssen, Handok, LG Chem, Novartis, Pfizer, SL VaxiGen, VigenCell, Aston Bioscience, Ingenium, Amgen, Sanofi Genzyme, Takeda, Meiji Pharm Co. and GreenCross Phar: Consultancy; AML-Hub, APBMT, ICBMT, APLC, Novartis and BMS: Other: and leadership or fiduciary roles in other board, society, committee or advocacy group ; Jazz Pharmaceuticals, Takeda, Astellas, AbbVie and APLC: Other: Travel; BL&H: Research Funding.